Pfizer and BioNTech SE entered a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY, the companies’ COVID-19 vaccine, to the EU, with an option for the EC to request up to an additional 900 million doses.
 
This new agreement is in addition to the 600 million doses already committed to the EU through 2021. The additional 900 million agreed doses are expected to be delivered on a monthly schedule beginning December 2021 and continuing into 2023. As part of the agreement, the EC also has an option to increase the number of doses delivered by up to an additional 900 million, bringing the total number of potential doses delivered to the EC, inclusive of all agreements, to up to 2.4 billion. All doses for the EC are planned to be manufactured in the EU.
 
The vaccine, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the EU, and the holder of emergency use authorizations or equivalent in the U.S. (jointly with Pfizer), UK, Canada and other countries in advance of a planned application for full marketing authorizations in these countries.